Articles

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

Servicio de Hematología, Hospital Universitario de Salamanca, CIC, IBMCC (USAL-CSIC), Salamanca, Spain
Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria (AOU) S. Giovanni Battista, Torino, Italy
Dana-Farber Cancer Institute, Boston, MA, USA
Hospital Universitario 12 de Octubre, Madrid, Spain
Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria (AOU) S. Giovanni Battista, Torino, Italy
Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria (AOU) S. Giovanni Battista, Torino, Italy
Servicio de Hematología, Hospital Universitario de Salamanca, CIC, IBMCC (USAL-CSIC), Salamanca, Spain
Università degli Studi di Catania, Ospedale Ferrarotto, Catania, Italy
Takeda Pharmaceuticals International Co., Cambridge, MA, USA
Janssen Research & Development, Beerse, Belgium
Janssen Global Services, Raritan, NJ, USA
Janssen Research & Development, Horsham, PA, USA
Clinica Universidad de Navarra, Centro Investigación Medica Aplicada, Pamplona, Spain
Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria (AOU) S. Giovanni Battista, Torino, Italy
Vol. 99 No. 6 (2014): June, 2014 https://doi.org/10.3324/haematol.2013.099341